Gilead Sciences, Inc. (GILD) Holdings Raised by Assetmark Inc.
Assetmark Inc. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 74.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 79,116 shares of the biopharmaceutical company’s stock after acquiring an additional 33,743 shares during the quarter. Assetmark Inc.’s holdings in Gilead Sciences were worth $5,600,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Seizert Capital Partners LLC raised its position in Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after acquiring an additional 27,547 shares in the last quarter. Investment Centers of America Inc. raised its position in Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after acquiring an additional 1,958 shares in the last quarter. Fagan Associates Inc. raised its position in Gilead Sciences by 2.6% during the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after acquiring an additional 845 shares in the last quarter. Dai Ichi Life Insurance Company Ltd raised its position in Gilead Sciences by 7.6% during the second quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock valued at $11,327,000 after acquiring an additional 11,299 shares in the last quarter. Finally, Capital Asset Advisory Services LLC purchased a new position in Gilead Sciences during the second quarter valued at approximately $875,000. 76.23% of the stock is owned by institutional investors and hedge funds.
Shares of Gilead Sciences, Inc. (GILD) opened at $75.88 on Tuesday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $96,951.29, a price-to-earnings ratio of 7.75, a P/E/G ratio of -1.24 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.75 EPS. research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.74%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
In related news, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock worth $37,404,139 in the last quarter. Company insiders own 1.30% of the company’s stock.
Several analysts have commented on GILD shares. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Thursday, August 31st. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective on the stock. in a report on Monday, August 28th. Wells Fargo & Company raised their price objective on Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a report on Wednesday, September 6th. Oppenheimer initiated coverage on Gilead Sciences in a report on Thursday, October 5th. They issued a “market perform” rating on the stock. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $85.11.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Holdings Raised by Assetmark Inc.” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/12/gilead-sciences-inc-gild-holdings-raised-by-assetmark-inc.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.